
News from innate-pharma.com
We’ve assigned a media bias rating of unknown to Innate-pharma.com. You can read more about our methodology here.
We’ve assigned a rating of Unknown factuality to Innate-pharma.com. You can read more about how we’ve determined Innate-pharma.com’s credibility and reliability as a news source here: https://groundnews.lakegeneva.lib.wi.us/rating-system.
Media Bias Ratings
Do you diasgree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Innate Pharma highlights durable responses to lacutamab in Sezary syndrome and mycosis fungoides
Velo3D Announces First Quarter 2025 Financial Results
59% Center coverage: 106 sources